A Phase III, Open-label, Randomised, Multicentre Study to Evaluate AZD0120 in Participants With Relapsed Refractory Multiple Myeloma.

by | Feb 6, 2026 | Clinical Trials | 0 comments

​ Conditions: Relapsed Refractory Multiple Myeloma

Interventions: Biological: AZD0120; Drug: Daratumumab; Drug: Carfilzomib; Drug: Dexamethasone; Drug: Bortezomib; Drug: Pomalidomide

Sponsors: AstraZeneca

Not yet recruiting Conditions: Relapsed Refractory Multiple Myeloma
Interventions: Biological: AZD0120; Drug: Daratumumab; Drug: Carfilzomib; Drug: Dexamethasone; Drug: Bortezomib; Drug: Pomalidomide
Sponsors: AstraZeneca
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *